Nisha Andany

Dr. Nisha Andany is a member of the Ontario COVID-19 Science Advisory Table.¹⁾

Andany completed a Masters in Public Health at the Harvard T.H. Chan School of Public Health in 2018.²⁾

Andany is a member of the Drugs & Biologics Clinical Practice Guidelines Working Group on the Ontario COVID-19 Science Advisory Table. In this role, she co-authored a paper advocating against using ivermectin for prophylaxis or treatment of COVID-19 on the grounds that “inappropriate use of ivermectin for COVID-19 may make it unavailable for patients who could benefit from its use (i.e., patients with serious parasitic infections) and reduce the already limited supply of ivermectin in Canada.”³⁾ Another paper bearing her name described azithromycin, bamlanivimab, colchicine, hydroxychloroquine, ivermectin, lopinavir-ritonavir, and vitamin D as “non-recommended therapies” which “either have demonstrable harm or lack sufficient evidence from randomized trials to warrant their use.” They advocated instead for use of dexamethasone, as well as monoclonal antibody treatments casirivimab and imdevimab (produced by Regeneron).^{4) 5)}

Andany is employed as an Infectious Diseases and HIV Specialist at Sunnybrook Health Sciences Centre. She works as Educational Lead, staff physician, and Affiliate Scientist, Evaluative Clinical Sciences, Integrated Community Program.⁶⁾ She participated in the centre's COVIDEO telehealth program.^{7) 8)}

Her relevant publications include:

• October 2020: Pneumocystis jirovecii pneumonia prophylaxis in a 42-year-old woman on immunosuppressive therapy. Andany discloses funding from Janssen, GlaxoSmithKline and Gilead for other HIV research.⁹⁾

• September 1, 2020: Home or Cabin: Community Care for Coronavirus Disease 2019¹⁰⁾

* January 2020: Prevalence and correlates of early-onset menopause among women living with HIV in Canada. Funded by the Canadian Institutes of Health Research (CIHR), CIHR Canadian HIV Trials Network, Ontario HIV Treatment Network, the Academic Health Science Centres Alternative Funding Plans (AFP) Innovation Fund, and Fonds de Recherche du Québec—Santé. Presented at the 7th International Workshop on HIV and Women in Seattle, Washington (February 11-12, 2017), funded by Gilead. Also presented at the Conference on Retroviruses and Opportunistic Infections (February 13-16) in Seattle, funded by Merck, ViiV Healthcare, AbbVie, Hologic and Cepheid.

Andany has received funding for HIV research from Janssen, GlaxoSmithKline and Gilead.^{11) 12) 13)}